M
Mathilde E. Boon
Researcher at University of Groningen
Publications - 110
Citations - 2776
Mathilde E. Boon is an academic researcher from University of Groningen. The author has contributed to research in topics: Cervical screening & Cervical intraepithelial neoplasia. The author has an hindex of 24, co-authored 110 publications receiving 2638 citations.
Papers
More filters
Journal ArticleDOI
Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial
N. W. J. Bulkmans,J. Berkhof,Lawrence Rozendaal,F.J. van Kemenade,A. J. P. Boeke,Saskia Bulk,Feja J. Voorhorst,René H.M. Verheijen,K. van Groningen,Mathilde E. Boon,W. Ruitinga,M. van Ballegooijen,Peter J.F. Snijders,Chris J.L.M. Meijer +13 more
TL;DR: The implementation of HPV DNA testing in cervical screening leads to earlier detection of CIN3+ lesions, which could permit an extension of the screening interval.
Journal ArticleDOI
The Uniform Approach to Breast Fine Needle Aspiration Biopsy
Marluce Bibbo,Andrea Abati,Alex Ferenczy,Juliette Robitaille,Eduardo L. Franco,Jocelyne Arseneau,Ralph M. Richart,Thomas C. Wright,Tarik M. Elsheikh,Edward G. Bernacki,Henry B. Burch,Kenneth D. Burman,H. Lester Reed,Leigh Buckner,Tracy Raber,James L. Ownbey,Joan Cangiarella,Dick H. Verbeek,Frank Smedts,Carolien W. Wijnen-Dubbers,Marcel Mravunac,Antonio Cajigas,Edward Savala,Paul Elgert,Thomas L. Slamovits,Mark J. Suhrland,Michael E. Bailey,Richard W. Brown,John P. DiTomasso,Ibrahim Ramzy,Dina R. Mody,Rui Luzzatto,Mathilde E. Boon,Isabel Ojanguren,Eva Castellà,Mariona Llatjós,Aurelio Ariza,José J. Navas Palacios,Brian W. Loggie,Ronald A. Fleming,Kim R. Geisinger,Shin-ichirou Jinza,Masayuki Iki,Sumio Noguchi,Taro Shuin,Yoshinobu Kubota,Yasuo Takano,Mitsunobu Masuda,Sana Tabbara,Nahla Acoury,Mary K. Sidawy,Barbara A. Centeno,Wanda M. Szyfelbein,Gilbert H. Daniels,Austin L. Vickery,Philip T. Cagle,Sanjay K. Sinha,Usha Rani Singh,Arati Bhatia,Tsu-Yi Chao,Wen-Yaw Chiou,Jia-Guang Liang,Tang-Yi Tsao,Nicholas J. Mulvany,Linda K. Green,Jim Griffin,Seung-Sook Lee,Kyung-Ja Cho,Husain A. Saleh,Ghada Khatib,Ja-June Jang,Eui Keun Ham,Perikala V. Kumar,Seyyed Mohammad Owji,A.A. Khezri,Živa Pohar-Marinšek,Marija Us-Krasovec,İbrahim Öztek,Hüseyin Baloğlu,Necdet Üskent,Zafer Kartaloglu,Ergun Uçmaklı,Recep Aydilek,Osman Dorkip,Mustafa Yaylaci,Melih Özel,Clyde B. Schechter,John C. Papadimitriou,Lynne V. Abruzzo,Patricia M. Bourquin,Cinthia B. Drachenberg,Janet F. Stastny,Alan C. Harris,Jonathan Ben-Ezra,Suhail Nasim,William J. Frable,Henryk A. Domanski,Esperanza Carabias,Patricia Dhimes,Pedro de Agustín,Eduardo Gutierrez,Esther Ravinsky,Janice R. Safneck,Nick Chantziantoniou,Ji Shin Lee,Min Cheol Lee,Chang Soo Park,Sang Woo Juhng,Yasmin Yusuf,Augusta H. Belmonte,Victor Tchertkoff +110 more
Journal ArticleDOI
Prognostic indicators in breast cancer--morphometric methods.
J. P. A. Baak,P. H. J. Kurver,A. J. E. De Snoo‐Niewlaat,S. De Graef,B. Makkink,Mathilde E. Boon +5 more
TL;DR: Morphometric methods seem possible to predict the outcome of individual patients more accurately than with the usual staging/grading methods, and might prove to be useful in the selection of patients for adjuvant chemotherapy.
Journal ArticleDOI
PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes
Lawrence Rozendaal,J Westerga,J C van der Linden,J. M. M. Walboomers,Feja J. Voorhorst,Ellen K. J. Risse,Mathilde E. Boon,C. J. L. M. Meijer +7 more
TL;DR: High risk HPV testing is superior to neural network based screening in identifying women at risk of developing CIN III, and for women with normal cytology and borderline changes and a negative high risk HPV test, the screening interval can be considerably prolonged.
Journal Article
Consequences of the introduction of combined spatula and Cytobrush sampling for cervical cytology. Improvements in smear quality and detection rates.
TL;DR: It is anticipated that, with the large-scale introduction of the Cytobrush sampling method, fewer repeat smears will be required and, in addition, the observed relative increase of endocervical adenocarcinoma of the endocernix will be halted and there will be fewer false-negative smears.